Clinical Significance of Laboratory-determined Aspirin Poor
Responsiveness After Primary Percutaneous Coronary Intervention

J 2016

Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention

MRDOVIC, Igor; Mirko COLIC; Lydija SAVIC; Gordana KRLJANAC; Peter KRUŽLIAK et. al.

Basic information

Original name

Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention

Authors

MRDOVIC, Igor (688 Serbia); Mirko COLIC (688 Serbia); Lydija SAVIC (688 Serbia); Gordana KRLJANAC (688 Serbia); Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution); Ratko LASICA (688 Serbia); Milika ASANIN (688 Serbia); Sanja STANKOVIC (688 Serbia) and Jelena MARINKOVIC (688 Serbia)

Edition

CARDIOVASCULAR DRUGS AND THERAPY, DORDRECHT, SPRINGER, 2016, 0920-3206

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Netherlands

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 2.820

RIV identification code

RIV/00216224:14110/16:00100476

Organization unit

Faculty of Medicine

DOI

https://doi.org/10.1007/s10557-016-6643-8

UT WoS

000375384700006

EID Scopus

2-s2.0-84957603158

Keywords in English

Aspirin resistance; Primary PCI; Clinical outcome

Abstract

In the original language

Aims The objective of the present substudy was to examine whether aspirin poor/high responsiveness (APR/AHR) is associated with increased rates of major adverse cardiovascular events (MACE) and serious bleeding after primary percutaneous coronary intervention (PPCI). Methods We analyzed 961 consecutive ST-elevation acute myocardial infarction patients who underwent PPCI between February 2008 and June 2011. Multiplate analyser (Dynabite, Munich, Germany) was used for the assessment of platelet reactivity. APR/AHR were defined as the upper/lower quintiles of ASPI values, determined 24 h after aspirin loading. APR patients were tailored using 300 mg maintenance dose for 30 days. The co-primary end points at 30 days were: MACE (death, non-fatal infarction, ischemia-driven target vessel revascularization and ischemic stroke) and serious bleeding according to the BARC classification. Results One hundred and 90 patients were classified as APR, and 193 patients as AHR. At admission, compared with aspirin sensitive patients (ASP), patients with APR had more frequently diabetes, anterior infarction and heart failure, while AHR patients had reduced values of creatine kinase, leukocytes, heart rate and systolic blood pressure. Compared with ASP, the rates of 30-day primary end points did not differ neither in APR group including tailored patients (MACE, adjusted OR 1.02, 95% CI 0.47-2.17; serious bleeding, adjusted OR 1.92, 95% CI 0.79-4.63), nor in patients with AHR (MACE, adjusted OR 1.58, 95% CI 0.71-5.51; serious bleeding, adjusted OR 0.69, 95% CI 0.22-2.12). Conclusions The majority of APR patients were suitable for tailoring. Neither APR including tailored patients nor AHR were associated with adverse 30-day efficacy or safety clinical outcomes.

Cite

MRDOVIC, Igor; Mirko COLIC; Lydija SAVIC; Gordana KRLJANAC; Peter KRUŽLIAK; Ratko LASICA; Milika ASANIN; Sanja STANKOVIC and Jelena MARINKOVIC. Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. CARDIOVASCULAR DRUGS AND THERAPY. DORDRECHT: SPRINGER, 2016, vol. 30, No 2, p. 151-158. ISSN 0920-3206. Available from: https://doi.org/10.1007/s10557-016-6643-8.

@article{1412152,
   author = {Mrdovic, Igor and Colic, Mirko and Savic, Lydija and Krljanac, Gordana and Kružliak, Peter and Lasica, Ratko and Asanin, Milika and Stankovic, Sanja and Marinkovic, Jelena},
   article_location = {DORDRECHT},
   article_number = {2},
   doi = {https://doi.org/10.1007/s10557-016-6643-8},
   keywords = {Aspirin resistance; Primary PCI; Clinical outcome},
   language = {eng},
   issn = {0920-3206},
   journal = {CARDIOVASCULAR DRUGS AND THERAPY},
   title = {Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention},
   volume = {30},
   year = {2016}
}

TY  - JOUR
ID  - 1412152
AU  - Mrdovic, Igor - Colic, Mirko - Savic, Lydija - Krljanac, Gordana - Kružliak, Peter - Lasica, Ratko - Asanin, Milika - Stankovic, Sanja - Marinkovic, Jelena
PY  - 2016
TI  - Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention
JF  - CARDIOVASCULAR DRUGS AND THERAPY
VL  - 30
IS  - 2
SP  - 151-158
EP  - 151-158
PB  - SPRINGER
SN  - 09203206
KW  - Aspirin resistance
KW  - Primary PCI
KW  - Clinical outcome
N2  - Aims The objective of the present substudy was to examine whether aspirin poor/high responsiveness (APR/AHR) is associated with increased rates of major adverse cardiovascular events (MACE) and serious bleeding after primary percutaneous coronary intervention (PPCI). Methods We analyzed 961 consecutive ST-elevation acute myocardial infarction patients who underwent PPCI between February 2008 and June 2011. Multiplate analyser (Dynabite, Munich, Germany) was used for the assessment of platelet reactivity. APR/AHR were defined as the upper/lower quintiles of ASPI values, determined 24 h after aspirin loading. APR patients were tailored using 300 mg maintenance dose for 30 days. The co-primary end points at 30 days were: MACE (death, non-fatal infarction, ischemia-driven target vessel revascularization and ischemic stroke) and serious bleeding according to the BARC classification. Results One hundred and 90 patients were classified as APR, and 193 patients as AHR. At admission, compared with aspirin sensitive patients (ASP), patients with APR had more frequently diabetes, anterior infarction and heart failure, while AHR patients had reduced values of creatine kinase, leukocytes, heart rate and systolic blood pressure. Compared with ASP, the rates of 30-day primary end points did not differ neither in APR group including tailored patients (MACE, adjusted OR 1.02, 95% CI 0.47-2.17; serious bleeding, adjusted OR 1.92, 95% CI 0.79-4.63), nor in patients with AHR (MACE, adjusted OR 1.58, 95% CI 0.71-5.51; serious bleeding, adjusted OR 0.69, 95% CI 0.22-2.12). Conclusions The majority of APR patients were suitable for tailoring. Neither APR including tailored patients nor AHR were associated with adverse 30-day efficacy or safety clinical outcomes.
ER  -

MRDOVIC, Igor; Mirko COLIC; Lydija SAVIC; Gordana KRLJANAC; Peter KRUŽLIAK; Ratko LASICA; Milika ASANIN; Sanja STANKOVIC and Jelena MARINKOVIC. Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. \textit{CARDIOVASCULAR DRUGS AND THERAPY}. DORDRECHT: SPRINGER, 2016, vol.~30, No~2, p.~151-158. ISSN~0920-3206. Available from: https://doi.org/10.1007/s10557-016-6643-8.

Přehled o publikaci